{"id":375,"date":"2020-07-18T10:41:34","date_gmt":"2020-07-18T10:41:34","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=375"},"modified":"2020-07-18T10:41:34","modified_gmt":"2020-07-18T10:41:34","slug":"17-july-2020-hydroxychloroquine-did-not-substantially-reduce-symptom-severity-in-outpatients-with-early-mild-covid-19","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-hydroxychloroquine-did-not-substantially-reduce-symptom-severity-in-outpatients-with-early-mild-covid-19\/","title":{"rendered":"(17 July 2020) Hydroxychloroquine- did not substantially reduce symptom severity in outpatients with early, mild COVID-19"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial<\/p>\n<p>https:\/\/doi.org\/10.7326\/M20-4207<\/p>\n<p class=\"\">In a randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020 (ClinicalTrials.gov: NCT04308668) in symptomatic, non hospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset were included. The primary end point was change in overall symptom severity over 14 days. Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P &lt; 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29). Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages. Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial https:\/\/doi.org\/10.7326\/M20-4207 In a randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020 (ClinicalTrials.gov: NCT04308668) in symptomatic, non hospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-hydroxychloroquine-did-not-substantially-reduce-symptom-severity-in-outpatients-with-early-mild-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(17 July 2020) Hydroxychloroquine- did not substantially reduce symptom severity in outpatients with early, mild COVID-19&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/375"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=375"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/375\/revisions"}],"predecessor-version":[{"id":376,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/375\/revisions\/376"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}